Cristina Meehan
Psychiatric/Mental Health · New Britain, CTNPI 1598240830
Payments from drug & device makers
Across 1,080 payments — averaging $207.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$114K
- Axsome Therapeutics, Inc.$91K
- Almatica Pharma LLC$11K
- Corium, LLC$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Neurocrine Biosciences, Inc.$907
- plus $3K from 18 others
What the payments were for
- Consulting fees$36,23916%
- Speaking & faculty fees$153,43168%
- Travel & lodging$14,9907%
- Food & beverage$19,7929%
- Education$260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 514 | $114,445 |
| Axsome Therapeutics, Inc. | 152 | $91,441 |
| Almatica Pharma LLC | 38 | $10,901 |
| Corium, LLC | 125 | $2,106 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 78 | $1,457 |
| Neurocrine Biosciences, Inc. | 26 | $907 |
| Alkermes, Inc. | 27 | $526 |
| Otsuka America Pharmaceutical, Inc. | 14 | $381 |
| Supernus Pharmaceuticals, Inc. | 12 | $349 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $329 |
| Sunovion Pharmaceuticals Inc. | 19 | $303 |
| E.r. Squibb & Sons, L.L.C. | 13 | $287 |
| Teva Pharmaceuticals USA, Inc. | 14 | $287 |
| Lundbeck LLC | 11 | $265 |
| Ironshore Pharmaceuticals Inc. | 6 | $119 |
| Jazz Pharmaceuticals Inc. | 1 | $113 |
| Collegium Pharmaceutical, Inc. | 4 | $72 |
| Merck | 2 | $42 |
| Tris Pharma Inc | 2 | $38 |
| Idorsia Pharmaceuticals US Inc | 2 | $36 |
| Johnson & Johnson | 1 | $23 |
| Tempus AI, Inc | 1 | $23 |
| Vertical Pharmaceuticals, LLC | 1 | $17 |
| Neuronetics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$224,478 in reported general payments places this provider in the 95th percentile of 679 psychiatric/mental health providers in Connecticut.
See all psychiatric/mental health providers in Connecticut →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 20 | $175,491 |
| VraylarCariprazine Hcl | 31 | $72,033 |
| Invega SustennaPaliperidone Palmitate | 13 | $39,932 |
| RexultiBrexpiprazole | 12 | $22,961 |
| Divalproex Sodium | 196 | $11,810 |
| Loreev XrLorazepam | 21 | $10,333 |
| Risperidone | 355 | $4,614 |
| Clozapine | 87 | $4,357 |
| Aripiprazole | 85 | $3,796 |
| Divalproex Sodium ErDivalproex Sodium | 88 | $3,770 |
| Trazodone Hcl | 130 | $3,622 |
| Lorazepam | 218 | $2,589 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 20 | $2,560 |
| Lurasidone Hcl | 14 | $2,485 |
| Lamotrigine | 79 | $2,388 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $907 | $175,49120 claims |
| AbbVieVraylar | $114,445 | $72,03331 claims |
| Johnson & JohnsonInvega Sustenna | $23 | $39,93213 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $381 | $22,96112 claims |
| Almatica Pharma LLCLoreev Xr, Sertraline Hcl | $10,901 | $11,882160 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 679 psychiatric/mental health providers in Connecticut.
Other psychiatric/mental health in New Britain
- Maria TapiaNew Britain$6K
- Victoria OdesinaNew Britain$6K
- Gina HigginsNew Britain$5K
- Samantha MrazBridgeport$87K
- Philip FrickManchester$31K
- Gia SantoroWest Haven$25K
- Donna DraperDanbury$19K
- Zahida SairitupaDanbury$19K
- Hui HuNorwich$19K
- Patrick GagnonMilford$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.